Press release
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children
About this update from Amgen Inc.
[{"type":"text","content":"SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-171\nDISCREET 16-week Data Demonstrated Statistically Significant Improvements in Genital Psoriasis, Including Skin, Itch and Quality of Life, in Patients With Moderate to Severe Disease2\nAdverse Events Were Consistent With Known Safety Profile of Otezla in Both Studies\nTHOUSAND OAKS, Calif., Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept. 7-10, 2022.\nSPROUT study in pediatric moderate to severe plaque psoriasis \nThe SPROUT study1 investigated the efficacy and safety of Otezla in pediatric patients aged 6 to 17 years with moderate to severe plaque psoriasis inadequately controlled by or intolerant to topical therapy. The primary endpoint of the static Physician's Global Assessment (sPGA) response (defined as an sPGA score of clear [0] or almost clear [1] with at least a 2-point reduction from baseline) at week 16 was met with a 33.1% sPGA response for Otezla versus 11.5% for placebo (95% CI: 11.2%, 32.1%; P","length":1842,"tagName":"div"}]